MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine

<p dir="ltr">Results from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.</p> <p> </p>